This study investigates malignant tumors using PET imaging targeting mesothelin (MSLN).
The study evaluates the effectiveness of MSLN-specific imaging agents for diagnosing and staging malignant tumors.
- Who can participate: Adults aged 18 or above with suspected or confirmed malignant tumors may participate. This includes those with pancreatic cancer, ovarian cancer, or lung adenocarcinoma. Healthy volunteers are also eligible.
- Study details: Participants will undergo PET/MR or PET/CT scans using investigational imaging agents. A placebo is not involved in this study.